Retrophin Announces Top-Line Results From Pivotal Phase 3 Fort Study In Pkan On-Track For 3Q 2019; Announces Enrollment Ongoing In Phase 3 Clinical Trials Of Sparsentan For Patients With Rare Nephropathies Fsgs And Igan

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!